KRAS and colorectal carcinoma: Our recent study also reported the absence of MAPK and PI3K/Akt pathways activation in CRC tumors compared to matched normal mucosa indicating that phosphorylated ERK/AKT may not be the appropriate downstream effectors to repress KRAS signaling (24).